OS of the AML patients included in the study according to different disease characteristics or therapeutic approach. (A) OS in the entire cohort of 8521 patients with AML according to type of AML (P < .001). (B) OS in secondary AML according to therapeutic approach (P < .001). (C) OS in secondary AML according to cytogenetic risk (P < .001). (D) OS in secondary AML according to NPM1 mutation (P < .001). (E) OS in secondary AML according to FLT3-ITD mutation (P = .45). (F) OS in secondary AML according to the different subgroups (P = .04).